Signant SmartSignals RTSM Enables Mid-Study Switch to Direct-to-Patient Clinical Supplies Model

Our Signant SmartSignals RTSM solution played an important role in a global pharmaceutical company’s multiregional phase 2 immunology study by facilitating a mid-study switch to a central pharmacy direct-to-patient model, which replaced daily in-clinic dosing of the investigational product.

Our flexible RTSM was adapted to enable the transition to at-home visits and even provided specialized reporting to ensure both sites and home healthcare nurses gained visibility to what they needed to fulfill their responsibilities.

Download the case study for more details.